News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Our centers are performing as expected or even better
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
An accomplished R&D leader and champion of the application of AI to drug discovery
Arco Lab now holds a 50% stake in Neviton
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Subscribe To Our Newsletter & Stay Updated
